Brief: Steris Q1 Adjusted EPS USD 2.34 Vs. IBES Estimate USD 2.26

Steris

06/08/2025 21:30

Overview

Steris fiscal Q1 2026 revenue rises 9% to $1.4 bln

Adjusted EPS for fiscal Q1 beats analyst expectations, per LSEG data

Co raises fiscal 2026 revenue outlook, expecting 8-9% growth

Outlook

Steris expects fiscal 2026 revenue to increase 8-9%

Still sees Adjusted EPS from continuing operations of $9.90 to $10.15

Company anticipates $820 mln free cash flow for fiscal 2026

Steris projects capital expenditures of $375 mln for fiscal 2026

Company sees tariffs reducing pre-tax profit by $45 mln

Result Drivers

FOREIGN CURRENCY - Revenue benefited from favorable foreign currency impacts, expected to continue throughout fiscal yr, per CEO Dan Carestio

HEALTHCARE SEGMENT - Healthcare revenue grew 8%, driven by 13% service revenue growth and improved volume and price

AST SEGMENT - Applied Sterilization Technologies revenue increased 13%, with significant growth in capital equipment revenue

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Adjusted EPS
Beat
$2.34
$2.26 (8 Analysts)
Q1 Adjusted Net Income
Beat
$231.20 mln
$222.20 mln (5 Analysts)
Q1 Revenue continuing operations
$1.40 bln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for STERIS plc is $278.00, about 19.5% above its August 5 closing price of $223.87

The stock recently traded at 22 times the next 12-month earnings vs. a P/E of 23 three months ago

Press Release: ID:nGNX5JvFzx

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)